The role of positron emission mammography in breast cancer imaging and management

Applied Radiology

Volumn 37, Issue 4, 2008, Pages 26-36

  Schilling, Kathy ^a,e   Conti, Peter ^b,f   Adler, Lee ^c,f   Tafra, Lorraine ^d,e  

^a Boca Raton Community Hospital   (United States)

^b USC PET Imaging Science Center   (United States)

^c Adler Institute for Advanced Imaging   (United States)

^d ANNE ARUNDEL MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Scientific Advisory Board of Naviscan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 5 ETHYL 2' FLUOROURACIL ARABINOSIDE C 11; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; FLUOROTHYMIDINE F 18; GLUCOSE TRANSPORTER 1; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201; TRACER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER SCREENING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREOPERATIVE CARE; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 42549137863     PISSN: 01609963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cancer Facts and Figures 2006. Atlanta, GA: American Cancer Society; 2006.
2. Mammography Accounting Office. GAO/HEHS-96-17. Initial impact of now federal law has been positive. Report to Congressional Committees, Washington, DC; U.S. Government Accounting Office; October 27, 1995.
3. Gwin JL, Eisenberg BL, Hoffman JP, et al. Incidence of gross and microscopic carcinoma in specimens from patients with breast cancer after re-excision lumpectomy. Ann Surg. 1993;218:729-734.
4. Hisadi K, Tonami N, Miyamae T, et al. Clinical evaluation of tumor imaging with 201 TI chloride. Radiology. 1978; 129:497-500.
5. Waxman AD, Ramanna L, Memsic LD, et al. Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med. 1993;34:18-23.
6. Kao CH, Wang SJ, and Liu TJ. The use of technefium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med. 1994;21:432-436.
7. Taillefer F. The role of 99mTc sestamibi and other conventional radiopharmaosuticals in breast cancer diagnosis. Semin Nucl Med.1999;29:16-40.
8. Waxman AD. The role of (99m)Tc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med. 1997;27(1):40-54.
9. Tofani A, Sciuto R, Semprebene A, et al. 99Tcm-MIBI scintimammography in 300 consecutive patents: Factors that may affect accuracy. Nucl Med Commun. 1999;20:1113-1121.
10. O'Connor MK, Phillips SW, Hruska CB, et al. Molecular breast imaging: Advantages and limitatons of a scintimammographic technique in patients with small breast tumors. Breast J. 2007;13(1):3-1 1. Comment in: Breast J. 2007;1 3(1):1-2.
11. Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med. 1989:15: 61-66.
12. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991;179:765-770.
13. Schirrmeister H, Kühn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with standard staging procedures. Eur J Nucl Med. 2001;28:351-358.
14. Rosé C, Dose J, Avril N. Positron emission tomography for the diagnosis of breast cancer. Nucl Mad Commun. 2002;23:613-618.
15. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2005;35:84-99.
16. Scheldhauer K, Walter C, Seemann MD. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging. 2004;31 (suppl 1):S70-S79.
17. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology. 1993;187:743-750.
18. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J ComputAssist Tomogr. 1993; 17:582-589.
19. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol. 1996; 14:1848-1857.
20. Avril N, Rosé CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol. 2000; 18:3495-3502.
21. Scheidhauer K, Schad A, Pietrzyk U, et al. Quantitative [18F]FDG positron emission tomography in primary breast cancer Clinical relevance and practicability. Eur J Nucl Med. 1996 23:618-623.
22. Mavi A, Urhan M, Yu JQ, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440-1446.
23. Tafra L, Cheng Z, Uddo J, et al. Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. Am J Surg. 2005;190:628-632.
24. Berg WA, Weinberg IN, Narayanan D, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J. 2006;12(4): 309-323.
25. Schilling KJ. High-resolution positron emission mammography in breast cancer. J Nuc Med. 2007; 48 (suppl 2):139P.
26. Adler, LP, Narayanan D, Gammage L, et al. Quantitative improvement in breast lesion detectabiltty on delayed images using high resolution positron emission mammography. J Nuc. Med. 2007;48 (suppl 2):369P.
27. Danforth DN Jr, Aloj L, Carrasquillo JA, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat. 2002;75(2):135-146.
28. Goerres GW, Michel SC, Fehr MK, et al. Follow-up of women with breast cancer: Comparison between MRI and FDG PET. Eur Radiol. 2003;13: 1635-1644.
29. van Oost FJ, van der Hoeven JJ, Hoeckstra OS, et al. Staging in patients with locoregionally recurrent breast cancer: Current practice and prospects for positron emission tomography. Eur J Cancer. 2004; 40:1545-1553.
30. Weir L, Worsley D, Bernstein V. The values of FDG positron emission tomography in the management of patients with breast cancer. Breast J. 2005; 11:204-209.
31. Kim SJ, Kim SK, Lee ES, et al. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol. 2004;15:1352-1357.
32. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol.2000; 18:1676-1688.
33. Chen X, Moore MO, Lehman CD, et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol. 2004; 11: 1115-1124.
34. Shields AF. Positron emission tomography measurement of tumor metabolism and growth: Its expanding role in oncology. Mol Imaging Bid. 2006; 8(3): 141-150.
35. Conti PS, Alauddin MM, Fissekis JR, et al. Synthesis of 2′-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11 C]-FMAU): A potential nuclecside analogue for in vivo study of cellular proliferation with PET. Nucl Med Biol. 1995;22: 783-789.
36. Alauddin MM, Conti PS, Fisselkis JD. Synthesis of [18F]-labeled 2′-deoxy-2′fluoro-5-methyl-1-beta-D-arabinofuranosyluracil. J Label Compd Radiopharm. 2002;45:583-590.
37. Kumar P, Mercer J, Doerkson C, et al. Clinical production, stability studies and PET imaging with 16-alpha-[l8F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. J Pharm Pharm Sci. 2007;10:256S-265S.